Interaction of tumor-associated macrophages and cancer chemotherapy

References

• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. doi:10.1038/nri2216.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi:10.1038/nrc3599.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012 May;19(5):1508–1516. doi:10.1245/s10434-011-2108-2.
   PubMed Web of Science ®Google Scholar
• Liu B, Ezeogu L, Zellmer L, Yu B, Xu N, Joshua Liao D. Protecting the normal in order to better kill the cancer. Cancer Med. 2015;4(9):1394–1403. doi:10.1002/cam4.488.
   PubMed Web of Science ®Google Scholar
• Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, et al. Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl. 2013;6(1):1–10. doi:10.1111/eva.12021.
   PubMed Web of Science ®Google Scholar
• Stakheyeva M, Riabov V, Mitrofanova I, Litviakov N, Choynzonov E, Cherdyntseva N, Kzhyshkowska J. Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Curr Pharm Des. 2017;23(32):4807–4826. doi:10.2174/1381612823666170714161703.
   PubMed Web of Science ®Google Scholar
• Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, et al. Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. J Clin Pathol. 2012;65:159–163. doi:10.1158/0008-5472.CAN-16-1170.
   PubMed Web of Science ®Google Scholar
• Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA, Almazyadi HAM, Kallmeyer K, Dandara C, Pepper MS, et al. Role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;21;18(7):E1586. doi:10.3390/ijms18071586.
   Web of Science ®Google Scholar
• Mozaffari F, Lindemalm C, Choudhury A, Granstam-Björneklett H, Helander I, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer. 2007;97(1):105–111. doi:10.1038/sj.bjc.6603840.
   PubMed Web of Science ®Google Scholar
• Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25. doi:10.1038/cdd.2013.67.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014;3(1):e27878. doi:10.4161/onci.27878.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012 Mar;122(3):787–795. doi:10.1172/JCI59643.
   PubMed Web of Science ®Google Scholar
• Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195–205. doi:10.1111/j.1365-2249.2011.04515.x.
   PubMed Web of Science ®Google Scholar
• Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018 Oct 1;78(19):5492–5503. doi:10.1158/0008-5472.CAN-18-1367.
   PubMed Web of Science ®Google Scholar
• Mitrofanova I, Zavyalova M, Telegina N, Buldakov M, Riabov V, Cherdyntseva N, Kzhyshkowska J. Tumor-associated macrophages in human breast cancer parenchyma negatively correlate with lymphatic metastasis after neoadjuvant chemotherapy. Immunobiology. 2017 Jan;222(1):101–109. doi:10.1016/j.imbio.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med. 2010;42(3):161–170. doi:10.3109/07853890903405753.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Schaar B, Tallapragada S, Dorigo O. Tumor associated macrophages in gynecologic cancers. Gynecol Oncol. 2018;149(1):205–213. doi:10.1016/j.ygyno.2018.01.014.
   PubMed Web of Science ®Google Scholar
• Gupta V, Yull F, Khabele D. Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers (Basel). 2018;10(10):1–13. doi:10.3390/cancers10100366.
   Web of Science ®Google Scholar
• Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: A roadmap for multitargeting strategies. Oncogene. 2016;35(6):671–682. doi:10.1038/onc.2015.132.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Bögels M, Braster R, Nijland PG, Gül N, van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen RH, van Egmond M. Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunol. 2012;1(6):798–809. doi:10.4161/onci.20427.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25(3):315–322. doi:10.1007/s10555-006-9001-7.
   PubMed Web of Science ®Google Scholar
• Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5 MAR(March):1–13. doi:10.3389/fphys.2014.00075.
   Web of Science ®Google Scholar
• Huang W, Chan M, Chen M, Tsai T. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget. 2016;7(26):1;13. doi:10.18632/oncotarget.8101.
   Google Scholar
• Liu Z, Kuang W, Zhou Q, Zhang Y. TGF-β1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2/3 signalling pathway. Int J Mol Med. 2018;42(6):3395–3403. doi:10.3892/ijmm.2018.3923.
   PubMed Web of Science ®Google Scholar
• Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948098. doi:10.1155/2012/948098.
   PubMedGoogle Scholar
• Chen JJW, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003;9:729–737.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yan Y, Yang Y, Wang L, Li M, Wang J, Liu X, Duan X, Wang J. High infiltration of tumor-associated macrophages influences poor prognosis in human gastric cancer patients, associates with the phenomenon of EMT. Med(United States). 2016;95(6):1–6. doi:10.1097/MD.0000000000002636.
   Web of Science ®Google Scholar
• Makitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68+ Cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414–1421.
   PubMed Web of Science ®Google Scholar
• Yuan ZY, Luo RZ, Peng RJ, Sen WS, Xue C. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther. 2014;7:1475–1480. doi:10.2147/OTT.S61838.
   PubMed Web of Science ®Google Scholar
• Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159–163. doi:10.1136/jclinpath-2011-200355.
   PubMed Web of Science ®Google Scholar
• Yang J, Li X, Liu XP, Liu Y. The role of tumor-associated macrophages in breast carcinoma invasion and metastasis. Int J Clin Exp Pathol. 2015;8:6656–6664.
   PubMed Web of Science ®Google Scholar
• Buldakov M, Zavyalova M, Krakhmal N, Telegina N, Vtorushin S, Mitrofanova I, Riabov V, Yin S, Song B, Cherdyntseva N, et al. CD68+, but not stabilin-1+ tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiolog. 2017;222(1):31–38. doi:10.1016/j.imbio.2015.09.011.
   PubMed Web of Science ®Google Scholar
• Forssell J, Öberg Å, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13(5):1472–1479. doi:10.1158/1078-0432.CCR-06-2073.
   PubMed Web of Science ®Google Scholar
• Malesci A, Bianchi P, Celesti G, Basso G, Marchesi F, Grizzi F, Di Caro G, Cavalleri T, Rimassa L, Palmqvist R, et al. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncoimmunology. 2017;6(12):1–11. doi:10.1080/2162402X.2017.1342918.
   Web of Science ®Google Scholar
• Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z, Xu J. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014;21(9):3142–3150. doi:10.1245/s10434-014-3601-1.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y. Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2015 Oct;18(4):740–750. doi:10.1007/s10120-014-0422-7.
   PubMed Web of Science ®Google Scholar
• Shu QH, Ge YS, Ma HX, Gao XQ, Pan JJ, Liu D, Xu GL, Ma JL, Jia WD. Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. J Cell Mol Med. 2016;20(6):1024–1035. doi:10.1111/jcmm.12787.
   PubMed Web of Science ®Google Scholar
• Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7:6. doi:10.1371/journal.pone.0038541.
   Web of Science ®Google Scholar
• Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013;12(3):259–267. doi:10.7785/tcrt.2012.500312.
   PubMed Web of Science ®Google Scholar
• Yafei Z, Jun G, Guolan G. Correlation between macrophage infiltration and prognosis of ovarian cancer-a preliminary study. Biomed Res. 2016;27:305–312.
   Google Scholar
• Chen X, Chen J, Zhang W, Sun R, Liu T, Zheng Y, Wu Y. Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma. Oncotarget. 2017;8(68):112685–112696. doi:10.18632/oncotarget.22340.
   PubMedGoogle Scholar
• Cheng Z, Zhang D, Gong B, Wang P, Liu F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget. 2010;8(50):87244–87262. doi:10.18632/oncotarget.20244.
   Google Scholar
• Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306. doi:10.1186/1471-2407-12-306.
   Google Scholar
• Zhang WJ, Wang XH, Gao ST, Chen C, Xu XY, Sun Q, Zhou ZH, Wu GZ, Yu Q, Xu G, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res. 2018;222:93–101. doi:10.1016/j.jss.2017.09.035.
   PubMed Web of Science ®Google Scholar
• Riabov V, Yin S, Song B, Avdic A, Schledzewski K, Ovsiy I, Gratchev A, Llopis Verdiell M, Sticht C, Schmuttermaier C, et al. Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget. 2016;7:21. doi:10.18632/oncotarget.8857.
   Google Scholar
• Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Lai YR, Zhong JM, Wu HQ, Su Q, et al. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40(12):1790–1797. doi:10.1016/j.humpath.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Thorn AP, Daugaard S, Christensen LH, Christensen IJ, Petersen MM. YKL-40 protein in osteosarcoma tumor tissue. Apmis. 2016;124(6):453–461. doi:10.1111/apm.2016.124.issue-6.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46(3):333–340. doi:10.1016/j.lungcan.2004.05.010.
   PubMed Web of Science ®Google Scholar
• Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002;95(2):267–274. doi:10.1002/cncr.10644.
   PubMed Web of Science ®Google Scholar
• Liu T, Larionova I, Litviakov N, Riabov V, Zavyalova M, Tsyganov M, Buldakov M, Song B, Moganti K, Kazantseva P, et al. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology. 2018 Mar 13;7(6):e1436922. doi:10.1080/2162402X.2018.1436922.
   PubMed Web of Science ®Google Scholar
• Litviakov N, Tsyganov M, Larionova I, Ibragimova M, Deryusheva I, Kazantseva P, Slonimskaya E, Frolova I, Choinzonov E, Cherdyntseva N, et al. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2018 Jul;82(1):99–109. doi:10.1007/s00280-018-3594-8.
   PubMed Web of Science ®Google Scholar
• Ong SM, Tan YC, Beretta O, Jiang D, Yeap WH, Tai JJ, Wong WC, Yang H, Schwarz H, Lim KH, et al. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol. 2012 Jan;42(1):89–100. doi:10.1002/eji.201141825.
   PubMed Web of Science ®Google Scholar
• Aljabery F, Olsson H, Gimm O, Jahnson S, Shabo I. M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer. Urol Oncol Semin Orig Investig. 2018;36(4):159.e19-159.e26. doi:10.1016/j.urolonc.2017.11.020.
   Web of Science ®Google Scholar
• David C, Nance JP, Hubbard J, Hsu M, Binder D, Wilson EH. Stabilin-1 expression in tumor associated macrophages. Brain Res. 2012;24(1481):71–78. doi:10.1016/j.brainres.2012.08.048.
   Web of Science ®Google Scholar
• Larionova IV, Sevastyanova TN, Rakina AA, Cherdyntseva NV, Kzhyshkowska JG. Chitinase-like proteins as promising markers in cancer patients. Sib J Oncol. 2018;17(4):99–105. doi:10.21294/1814-4861-2018-17-4-99-105.
   Google Scholar
• Kzhyshkowska J, Yin S, Liu T, Riabov V, Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem. 2016 Mar;397(3):231–247. doi:10.1515/hsz-2015-0269.
   PubMed Web of Science ®Google Scholar
• Knorr T1, Obermayr F, Bartnik E, Zien A, Aigner T. YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes. Ann Rheum Dis. 2003 Oct;62(10):995–998. doi:10.1136/ard.62.10.995.
   PubMed Web of Science ®Google Scholar
• Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Tonin PN, Provencher DM, Mes-Masson A-M. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–254. doi:10.1002/cncr.22789.
   PubMed Web of Science ®Google Scholar
• Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci. 2009;38(4):283–290. doi:10.1016/j.ejps.2009.08.009.
   PubMed Web of Science ®Google Scholar
• De Palma M, Lewis CE. Macrophages limit chemotherapy. Cancer Discov. 2011;1(1):54–67. doi:10.1038/472303a.
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583–4594. doi:10.1158/1078-0432.CCR-10-0733.
   PubMed Web of Science ®Google Scholar
• Chauhan P, Sodhi A, Shrivastava A. Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells. Immunobiology. 2009;214(3):197–209. doi:10.1016/j.imbio.2008.07.012.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LTC, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, Sh VDB. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480–2492. doi:10.1158/0008-5472.CAN-12-3542.
   PubMed Web of Science ®Google Scholar
• Sugimura K, Miyata H, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y, et al. High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg Oncol. 2015;111(6):752–759. doi:10.1002/jso.23881.
   PubMed Web of Science ®Google Scholar
• Bryniarski K, Szczepanik M, Ptak M, Zemelka M, Ptak W. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol Rep. 2009;61(3):550–557. doi:10.1016/S1734-1140(09)70098-2.
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 2014;156(3):590–602. doi:10.1016/j.cell.2013.12.041.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226–239. doi:10.1111/j.1365-2567.2010.03357.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641–648. doi:10.1007/s00262-006-0225-8.
   PubMed Web of Science ®Google Scholar
• Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010;33(1):53–59. doi:10.1097/CJI.0b013e3181b56af4.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology. 2013;2(12):41–44. doi:10.4161/onci.27158.
   Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729–741. doi:10.1016/j.immuni.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Laoui D, Van Overmeire E, Van Ginderachter JA. Unsuspected allies: chemotherapy teams up with immunity to fight cancer. Eur J Immunol. 2013;43(10):2538–2542. doi:10.1002/eji.201344042.
   PubMed Web of Science ®Google Scholar
• Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Ewald AJ, Fein M, Rasch MG, Tan YX, et al. Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance. Cancer Cell. 2012;21(4):488–503. doi:10.1016/j.ccr.2012.02.017.
   PubMed Web of Science ®Google Scholar
• Wang B, Xu D, Yu X, Ding T, Rao H, Zhan Y, Zheng L, Li L. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol. 2011;18(9):2585–2593. doi:10.1245/s10434-011-1609-3.
   PubMed Web of Science ®Google Scholar
• Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2015;65(10):1710–1720. doi:10.1136/gutjnl-2015-309193.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249–262. doi:10.1016/j.ccr.2013.01.008.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):10430. doi:10.1097/FPC.0b013e32833ffb56.
   Google Scholar
• Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677–2681. doi:10.1091/mbc.E14-04-0916.
   PubMed Web of Science ®Google Scholar
• Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010. doi:10.4061/2010/201367.
   Google Scholar
• Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, et al. 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancers (Basel). 2010;2(3):1717–1730. doi:10.3390/cancers2031717.
   PubMedGoogle Scholar
• Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Futur Oncol. 2005;1(1):7–17. doi:10.1517/14796694.1.1.7.
   PubMedGoogle Scholar
• D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111(4):646–650. doi:10.1038/bjc.2014.149.
   PubMed Web of Science ®Google Scholar
• Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75(17):3479–3491. doi:10.1158/0008-5472.CAN-14-3587.
   PubMed Web of Science ®Google Scholar
• Harrison DJ. Molecular mechanisms of drug resistance in tumours. J Pathol. 1995;175(1):7–12. doi:10.1002/path.1711750103.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer. 2002 Jan 1;2:48. doi:10.1038/nrc706.
   PubMed Web of Science ®Google Scholar
• Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–313. doi:10.1038/nature10762.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;212(4):435–445. doi:10.1084/jem.20150295.
   PubMed Web of Science ®Google Scholar
• Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25(23):2465–2479. doi:10.1101/gad.180331.111.
   PubMed Web of Science ®Google Scholar
• Castrellon AB, Pidhorecky I, Valero V, Raez LE. The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. Oncol Rev. 2017;11(1):7–12. doi:10.4081/oncol.2017.324.
   Web of Science ®Google Scholar
• Su Y-W, Hung C-Y, Lam H-B, Chang Y-C, Yang P-S. A single institution experience of incorporation of cisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown BRCA mutation status. Clin Med Insights Oncol. 2018;12. doi:10.1177/1179554918794672.
   PubMed Web of Science ®Google Scholar
• Singh RAK, Sodhi A. Antigen presentation by cisplatin-activated macrophages: role of soluble factor(s) and second messengers. Immunol Cell Biol. 1998;76(6):513–519. doi:10.1046/j.1440-1711.1998.00769.
   PubMed Web of Science ®Google Scholar
• Chauhan P, Sodhi A, Tarang S. Cisplatin-treated murine peritoneal macrophages induce apoptosis in L929 cells: role of Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1. Anticancer Drugs. 2007;18(2):187–196. doi:10.1097/CAD.0b013e3280104b11.
   PubMed Web of Science ®Google Scholar
• Owen W, Thurs K. Basal cell carcinoma presenting as a nonhealing wound case report. Adv Skin Wound Care. 2009;August:353–355. doi:10.1097/01.ASW.0000358640.76210.49.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016 Mar 15;44(3):450–462. 2016;15(5):477–91. doi:10.1016/j.immuni.2016.02.015.
   PubMed Web of Science ®Google Scholar
• Cao Q, Yan X, Chen K, Huang Q, Melancon MP, Lopez G, Cheng Z, Li C. Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials. 2018;152:63–76. doi:10.1016/j.biomaterials.2017.10.036.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet?. Science. 2013 Jan 18;339(6117):286–291. doi:10.1126/science.1232227.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci. 2011;108(30):12425–12430. doi:10.1073/pnas.1106645108.
   PubMed Web of Science ®Google Scholar
• Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, Shen L. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):1–13. doi:10.1186/s13046-017-0528-y.
   PubMed Web of Science ®Google Scholar
• Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, Gil Z. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33(29):3812–3819. doi:10.1038/onc.2013.357.
   PubMed Web of Science ®Google Scholar
• Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010;120(10):3421–3431. doi:10.1172/JCI42918.
   Google Scholar
• Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle. 2004;3(12):1516–1519. doi:10.4161/cc.3.12.1289.
   PubMed Web of Science ®Google Scholar
• Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp. 2003;70:263–276. doi:10.1042/bss0700263.
   PubMedGoogle Scholar
• Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66(10):5242–5250. doi:10.1158/0008-5472.CAN-05-4463.
   PubMed Web of Science ®Google Scholar
• Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Muller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci. 2010;107(6):2497–2502. doi:10.1073/pnas.0907240107.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–472. doi:10.1016/j.ccell.2015.02.015.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67. doi:10.1158/2159-8274.CD-10-0028.
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000;355:735–740.
   PubMed Web of Science ®Google Scholar
• Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer. 2016;4(1):1–13. doi:10.1186/s40425-016-0169-2.
   Web of Science ®Google Scholar
• Soares KC, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Wamwea A, Bigelow E, Lutz E, Liu L, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2014;00(00):1–11. doi:10.1097/CJI.0000000000000062.
   Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871–881. doi:10.1084/jem.20050930.
   PubMed Web of Science ®Google Scholar
• Aharinejad S, Schäfer R, Paulus P, Sioud M, Hofmann M, Zins K, Stanley ER, Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004;64(15):5378–5384. doi:10.1158/0008-5472.CAN-04-0961.
   PubMed Web of Science ®Google Scholar
• Paulus P, Stanley ER, Schäfer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006;66(8):4349–4356. doi:10.1158/0008-5472.CAN-05-3523.
   PubMed Web of Science ®Google Scholar
• Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–2656. doi:10.1158/0008-5472.CAN-06-1823.
   PubMed Web of Science ®Google Scholar
• Abraham D, Zins K, Sioud M, Lucas T, Schäfer R, Stanley ER, Aharinejad S. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer. 2010;126(6):1339–1352. doi:10.1002/ijc.24859.
   PubMed Web of Science ®Google Scholar
• Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128–1141. doi:10.1158/0008-5472.CAN-12-2731.
   PubMed Web of Science ®Google Scholar
• Linde N, Lederle W, Depner S, Van Rooijen N, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol. 2012;227(1):17–28. doi:10.1002/path.3989.
   PubMed Web of Science ®Google Scholar
• Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, Merquiol E, Ben-Nun Y, Miller V, Rachman-Tzemah C, et al. Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Rep. 2016;17(5):1344–1356. doi:10.1016/j.celrep.2016.09.083.
   PubMed Web of Science ®Google Scholar
• Duhamel M, Rose M, Rodet F, Murgoci A-N, Zografidou L, Régnier-Vigouroux A, Abeele FV, Kobeissy F, Nataf S, Pays L, et al. Paclitaxel treatment and PC1/3 knockdown in macrophages is a promising anti-glioma strategy as revealed by proteomics and cytotoxicity studies. Mol Cell Proteomics. 2018;mcp.RA117.000443. doi:10.1074/mcp. RA117.000443.
   PubMed Web of Science ®Google Scholar
• Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol. 2015;7(2):165–176. doi:10.4254/wjh.v7.i2.165.
   PubMed Web of Science ®Google Scholar